Higher expression of estrogen receptor in primary platinum-resistant high grade serous ovarian cancers

Introduction: Endocrine therapy for ovarian cancer is an option and commonly used in pretreated patients. Unfortunately, the benefit of this therapy is small with low response rates. Prognosis and treatment benefit depends on estrogen (ER) and progesterone receptor (PR) expression. The aim of this study is to determine the expression rate of ER and PR in a high-risk serous ovarian cancer cohort. Methods: Matched primary and recurrent high-grade serous ovarian cancers collected between 1985 and 2003 at the University Hospital Basel within a Tissue Microarray were used for this study (n = 80). All patients had com…